2025年欧洲癌症死亡率预测:聚焦乳腺癌
该研究基于世界卫生组织与联合国数据库1970年以来欧盟、五个人口最多国家及英国的癌症死亡数据,用泊松连接点回归与线性回归预测2025年癌症死亡数与年龄标化率。预测欧盟2025年约128万例癌症死亡,男性年龄标化率120.9/10万(较2020年下降3.5%),女性79.1/10万(下降1.2%);乳腺癌死亡率在所有国家均呈有利趋势,欧盟50-69岁女性下降9.8%、70-79岁下降12.4%。
要点
- 预测欧盟2025年约128万例癌症死亡,男性年龄标化率120.9/10万(较2020年下降3.5%),女性79.1/10万(下降1.2%)。
- 欧盟女性肺癌(+3.8%)与膀胱癌(+1.9%)死亡率预测上升,男性胰腺癌(+2.0%)、女性胰腺癌(+3.0%)亦上升。
核心结论
- 欧盟乳腺癌死亡率自1990年以来下降30%,归因于预防、治疗和早期发现的进步。
- 男女肺癌趋势相反反映吸烟模式差异,欧盟女性肺癌死亡率仍在上升但增幅小于前十年。
- 胰腺癌持续不利趋势可能与肥胖患病率增加和治疗进展有限相关,需要持续关注。
研究设计与样本
- 从世界卫生组织与联合国数据库获取欧盟、法国、德国、意大利、波兰、西班牙和英国1970年以来全部癌症及主要部位的 population 数据与死亡证明。
- 通过泊松连接点回归识别近期趋势,考虑最近趋势段的斜率,用线性回归计算2025年估计值。
- 通过将1988年峰值率应用于后续人口数据,计算1989至2025年避免的死亡数。
主要发现
- 预测欧盟2025年癌症死亡1 280 000例,男性年龄标化率120.9/100 000(较2020年下降3.5%),女性79.1/100 000(下降1.2%)。
- 预测英国2025年癌症死亡173 000例,男性年龄标化率101.2/100 000(下降10.1%),女性82.1/100 000(下降6.3%)。
- 欧盟男性胰腺癌死亡率上升2.0%,女性胰腺癌上升3.0%,女性肺癌上升3.8%,女性膀胱癌上升1.9%。
- 欧盟50-69岁女性乳腺癌死亡率下降9.8%,70-79岁女性下降12.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer. MATERIALS AND METHODS: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment. Deaths averted from 1989 to 2025 were calculated by applying the 1988 peak rate to subsequent population data. RESULTS: We estimated 1 280 000 cancer deaths in the EU in 2025, corresponding to age-standardised rates (ASRs) of 120.9/100 000 males (-3.5% versus 2020) and 79.1/100 000 females (-1.2%). In the UK, we predicted 173 000 cancer deaths and ASRs of 101.2/100 000 males (-10.1%) and 82.1/100 000 females (-6.3%). In the EU, favourable trends are predicted for major neoplasms, except pancreatic cancer, in males (+2.0%) and females (+3.0%), and lung (+3.8%) and bladder (+1.9%) cancers among females. Breast cancer mortality showed favourable trends in all countries. Substantial decreases were predicted for EU females aged 50-69 years (-9.8%) and 70-79 years (-12.4%). Between 1989 and 2025, we estimated about 6.8 million averted cancer deaths in the EU, including over 373 000 breast cancer deaths. Corresponding numbers for the UK were 1 500 000 and 197 000. CONCLUSION: EU breast cancer rates have fallen by 30% since 1990, due to advances in prevention, treatment, and early detection. Contrasting trends in lung cancer among males and females reflect differing tobacco smoking patterns. Female lung cancer mortality is still increasing in the EU, though less than in the previous decade. Persistent unfavourable pancreatic cancer trends can be related to the increasing prevalence of obesity and limited therapeutic advances, requiring continued attention.
引用
- Santucci C, Mignozzi S, Levi F, et al. European cancer mortality predictions for the year 2025 with focus on breast cancer. Ann Oncol. 2025. PMID: 40074664. doi:10.1016/j.annonc.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。